These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38706272)

  • 1. Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
    Liu H; Li J; Ziegemeier E; Adams S; McDade E; Clifford DB; Cao Y; Wang G; Li Y; Mills SL; Santacruz AM; Belyew S; Grill JD; Snider BJ; Mummery CJ; Surti G; Hannequin D; Wallon D; Berman SB; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sanchez-Valle R; Brooks WS; Gauthier S; Galasko D; Masters CL; Brosch J; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Bateman RJ; Llibre-Guerra JJ
    J Prev Alzheimers Dis; 2024; 11(3):558-566. PubMed ID: 38706272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
    Wagemann O; Liu H; Wang G; Shi X; Bittner T; Scelsi MA; Farlow MR; Clifford DB; Supnet-Bell C; Santacruz AM; Aschenbrenner AJ; Hassenstab JJ; Benzinger TLS; Gordon BA; Coalier KA; Cruchaga C; Ibanez L; Perrin RJ; Xiong C; Li Y; Morris JC; Lah JJ; Berman SB; Roberson ED; van Dyck CH; Galasko D; Gauthier S; Hsiung GR; Brooks WS; Pariente J; Mummery CJ; Day GS; Ringman JM; Mendez PC; St George-Hyslop P; Fox NC; Suzuki K; Okhravi HR; Chhatwal J; Levin J; Jucker M; Sims JR; Holdridge KC; Proctor NK; Yaari R; Andersen SW; Mancini M; Llibre-Guerra J; Bateman RJ; McDade E;
    JAMA Neurol; 2024 Jun; 81(6):582-593. PubMed ID: 38683602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model.
    Bateman RJ; Benzinger TL; Berry S; Clifford DB; Duggan C; Fagan AM; Fanning K; Farlow MR; Hassenstab J; McDade EM; Mills S; Paumier K; Quintana M; Salloway SP; Santacruz A; Schneider LS; Wang G; Xiong C;
    Alzheimers Dement; 2017 Jan; 13(1):8-19. PubMed ID: 27583651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.
    Mills SM; Mallmann J; Santacruz AM; Fuqua A; Carril M; Aisen PS; Althage MC; Belyew S; Benzinger TL; Brooks WS; Buckles VD; Cairns NJ; Clifford D; Danek A; Fagan AM; Farlow M; Fox N; Ghetti B; Goate AM; Heinrichs D; Hornbeck R; Jack C; Jucker M; Klunk WE; Marcus DS; Martins RN; Masters CM; Mayeux R; McDade E; Morris JC; Oliver A; Ringman JM; Rossor MN; Salloway S; Schofield PR; Snider J; Snyder P; Sperling RA; Stewart C; Thomas RG; Xiong C; Bateman RJ
    Rev Neurol (Paris); 2013 Oct; 169(10):737-43. PubMed ID: 24016464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
    Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal head-to-head comparison of
    Chen CD; McCullough A; Gordon B; Joseph-Mathurin N; Flores S; McKay NS; Hobbs DA; Hornbeck R; Fagan AM; Cruchaga C; Goate AM; Perrin RJ; Wang G; Li Y; Shi X; Xiong C; Pontecorvo MJ; Klein G; Su Y; Klunk WE; Jack C; Koeppe R; Snider BJ; Berman SB; Roberson ED; Brosch J; Surti G; Jiménez-Velázquez IZ; Galasko D; Honig LS; Brooks WS; Clarnette R; Wallon D; Dubois B; Pariente J; Pasquier F; Sanchez-Valle R; Shcherbinin S; Higgins I; Tunali I; Masters CL; van Dyck CH; Masellis M; Hsiung R; Gauthier S; Salloway S; Clifford DB; Mills S; Supnet-Bell C; McDade E; Bateman RJ; Benzinger TLS;
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2669-2682. PubMed ID: 37017737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease.
    Wang G; Li Y; Xiong C; Benzinger TLS; Gordon BA; Hassenstab J; Aschenbrenner AJ; McDade E; Clifford DB; Libre-Guerra JJ; Shi X; Mummery CJ; van Dyck CH; Lah JJ; Honig LS; Day G; Ringman JM; Brooks WS; Fox NC; Suzuki K; Levin J; Jucker M; Delmar P; Bittner T; Bateman RJ;
    Alzheimers Dement; 2024 Apr; 20(4):2698-2706. PubMed ID: 38400532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [DIAN/DIAN-J/DIAN-TU].
    Shimada H; Shoji M; Ikeuchi T; Suzuki K; Senda M; Ishii K; Matsuda H; Iwata A; Ihara R; Iwatsubo T; Mutoh K; Nakazawa E; Sekijima Y; Mori E; Ikeda M; Ikeda M; Kawakatsu S; Nakanishi A; Hashimoto M; Nunomura A; Matsubara E; Fukui M; Shirato T; Hirai K; Sakamoto M; Fujii H; Mori H
    Brain Nerve; 2017 Jul; 69(7):701-709. PubMed ID: 28739983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Wang G; Li Y; Xiong C; McDade E; Clifford DB; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Libre-Guerra JJ; McCullough A; Joseph-Mathurin N; Chen CD; Mummery C; Wendelberger BA; Gauthier S; Masellis M; Holdridge KC; Yaari R; Chatterjee S; Sims J; Delmar P; Kerchner GA; Bittner T; Hofmann C; Bateman RJ;
    Alzheimers Dement (Amst); 2022; 14(1):e12367. PubMed ID: 36348972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes toward clinical trials across the Alzheimer's disease spectrum.
    Nuño MM; Gillen DL; Dosanjh KK; Brook J; Elashoff D; Ringman JM; Grill JD
    Alzheimers Res Ther; 2017 Oct; 9(1):81. PubMed ID: 28978335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
    Salloway S; Farlow M; McDade E; Clifford DB; Wang G; Llibre-Guerra JJ; Hitchcock JM; Mills SL; Santacruz AM; Aschenbrenner AJ; Hassenstab J; Benzinger TLS; Gordon BA; Fagan AM; Coalier KA; Cruchaga C; Goate AA; Perrin RJ; Xiong C; Li Y; Morris JC; Snider BJ; Mummery C; Surti GM; Hannequin D; Wallon D; Berman SB; Lah JJ; Jimenez-Velazquez IZ; Roberson ED; van Dyck CH; Honig LS; Sánchez-Valle R; Brooks WS; Gauthier S; Galasko DR; Masters CL; Brosch JR; Hsiung GR; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Jack CR; Koeppe R; Snyder PJ; Aisen PS; Thomas RG; Berry SM; Wendelberger BA; Andersen SW; Holdridge KC; Mintun MA; Yaari R; Sims JR; Baudler M; Delmar P; Doody RS; Fontoura P; Giacobino C; Kerchner GA; Bateman RJ;
    Nat Med; 2021 Jul; 27(7):1187-1196. PubMed ID: 34155411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS).
    Tang M; Ryman DC; McDade E; Jasielec MS; Buckles VD; Cairns NJ; Fagan AM; Goate A; Marcus DS; Xiong C; Allegri RF; Chhatwal JP; Danek A; Farlow MR; Fox NC; Ghetti B; Graff-Radford NR; Laske C; Martins RN; Masters CL; Mayeux RP; Ringman JM; Rossor MN; Salloway SP; Schofield PR; Morris JC; Bateman RJ;
    Lancet Neurol; 2016 Dec; 15(13):1317-1325. PubMed ID: 27777020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force.
    Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B
    J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?
    Imbimbo BP; Lucca U; Watling M
    Neurol Genet; 2021 Feb; 7(1):e535. PubMed ID: 33575481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance and progress of DIAN/A4/API].
    Shimada H
    Nihon Rinsho; 2016 Mar; 74(3):417-22. PubMed ID: 27025079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials.
    Moulder KL; Snider BJ; Mills SL; Buckles VD; Santacruz AM; Bateman RJ; Morris JC
    Alzheimers Res Ther; 2013; 5(5):48. PubMed ID: 24131566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN).
    Cairns NJ; Perrin RJ; Franklin EE; Carter D; Vincent B; Xie M; Bateman RJ; Benzinger T; Friedrichsen K; Brooks WS; Halliday GM; McLean C; Ghetti B; Morris JC; ;
    Neuropathology; 2015 Aug; 35(4):390-400. PubMed ID: 25964057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
    Boerwinkle AH; Gordon BA; Wisch J; Flores S; Henson RL; Butt OH; McKay N; Chen CD; Benzinger TLS; Fagan AM; Handen BL; Christian BT; Head E; Mapstone M; Rafii MS; O'Bryant S; Lai F; Rosas HD; Lee JH; Silverman W; Brickman AM; Chhatwal JP; Cruchaga C; Perrin RJ; Xiong C; Hassenstab J; McDade E; Bateman RJ; Ances BM; ;
    Lancet Neurol; 2023 Jan; 22(1):55-65. PubMed ID: 36517172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
    Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
    JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.